Venture Life Group (LON:VLG) Shares Pass Above 50 Day Moving Average - Should You Sell?

Key Points

• Venture Life Group plc stock price surpassed its 50-day moving average during trading, reaching a high of GBX 59.29 ($0.80) before closing at GBX 58 ($0.78).
• The company reported a net margin of 1.44% and a return on equity of 0.99% in its last quarterly earnings, along with an estimated EPS of 6.14 for the current fiscal year.
• Insider Jerry Randall bought 50,000 shares at an average price of GBX 59 per share, indicating confidence in the company, which is owned 10.41% by corporate insiders.

Venture Life Group plc (LON:VLG - Get Free Report) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 57.19 ($0.77) and traded as high as GBX 59.29 ($0.80). Venture Life Group shares last traded at GBX 58 ($0.78), with a volume of 238,644 shares.

Venture Life Group Stock Performance

The firm has a fifty day moving average price of GBX 57.73 and a two-hundred day moving average price of GBX 48.46. The stock has a market capitalization of £72.63 million, a PE ratio of 96.73, a P/E/G ratio of 5.67 and a beta of 0.30. The company has a debt-to-equity ratio of 28.45, a current ratio of 2.22 and a quick ratio of 1.48.

Venture Life Group (LON:VLG - Get Free Report) last released its quarterly earnings data on Monday, June 30th. The company reported GBX 3.96 EPS for the quarter. Venture Life Group had a return on equity of 0.99% and a net margin of 1.44%. Research analysts expect that Venture Life Group plc will post 6.1391542 EPS for the current year.

Insider Transactions at Venture Life Group

In related news, insider Jerry Randall bought 50,000 shares of the company's stock in a transaction on Wednesday, July 2nd. The shares were acquired at an average price of GBX 59 per share, with a total value of £29,500. Company insiders own 10.41% of the company's stock.

Venture Life Group Company Profile

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, The Netherlands and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare, fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing. The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples.